Literature DB >> 10649254

Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma.

P Schrenk1, R Rieger, A Shamiyeh, W Wayand.   

Abstract

BACKGROUND: Axillary lymph node dissection for staging the axilla in breast carcinoma patients is associated with considerable morbidity, such as edema of the arm, pain, sensory disturbances, impairment of arm mobility, and shoulder stiffness. Sentinel lymph node biopsy electively removes the first lymph node, which gets the drainage from the tumor and should therefore be associated with nearly zero morbidity.
METHODS: Postoperative morbidity (increase in arm circumference, subjective lymphedema, pain, numbness, effect on arm strength and mobility, and stiffness) of the operated arm was prospectively compared in 35 breast carcinoma patients after axillary lymph node dissection (ALND) of Level I and II and 35 patients following sentinel lymph node (SN) biopsy.
RESULTS: Patient characteristics were comparable between the two groups. Postoperative follow-up was 15.4 months (range, 4-28 months) in the SN group and 17.0 months (range, 4-28 months) in the ALND group. Following axillary dissection, patients showed a significant increase in upper and forearm circumference of the operated arm compared with the SN patients, as well as a significantly higher rate of subjective lymphedema, pain, numbness, and motion restriction. No difference between the two groups was found regarding arm stiffness or arm strength, nor did the type of surgery affect daily living.
CONCLUSIONS: SN biopsy is associated with negligible morbidity compared with complete axillary lymph node dissection. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10649254     DOI: 10.1002/(sici)1097-0142(20000201)88:3<608::aid-cncr17>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  74 in total

1.  Prospective surveillance of breast cancer-related lymphoedema in the first-year post-surgery: feasibility and comparison of screening measures.

Authors:  J M Blaney; G McCollum; J Lorimer; J Bradley; R Kennedy; J P Rankin
Journal:  Support Care Cancer       Date:  2014-11-16       Impact factor: 3.603

2.  Perceptions of upper-body problems during recovery from breast cancer treatment.

Authors:  Louisa G Collins; Robyn Nash; Tracey Round; Beth Newman
Journal:  Support Care Cancer       Date:  2003-10-31       Impact factor: 3.603

3.  Risk factors for lymphedema in a prospective breast cancer survivorship study: the Pathways Study.

Authors:  Marilyn L Kwan; Jeanne Darbinian; Kathryn H Schmitz; Rebecca Citron; Paula Partee; Susan E Kutner; Lawrence H Kushi
Journal:  Arch Surg       Date:  2010-11

4.  Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients.

Authors:  Emin Yildirim; Ugur Berberoglu
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

5.  Risk factors for lymphedema after breast cancer treatment.

Authors:  Sandra A Norman; A Russell Localio; Michael J Kallan; Anita L Weber; Heather A Simoes Torpey; Sheryl L Potashnik; Linda T Miller; Kevin R Fox; Angela DeMichele; Lawrence J Solin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-26       Impact factor: 4.254

6.  Evaluation of sentinel lymph node metastasis alone guided by three-dimensional computed tomographic lymphography in video-assisted breast surgery.

Authors:  K Yamashita; K Shimizu
Journal:  Surg Endosc       Date:  2008-03-06       Impact factor: 4.584

7.  Video-assisted breast surgery can sample the second and third sentinel nodes to omit axillary node dissection for sentinel-node-positive patients.

Authors:  K Yamashita; K Shimizu
Journal:  Surg Endosc       Date:  2009-03-05       Impact factor: 4.584

8.  Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation?

Authors:  Jean-Cyril Bourre; Raoul Payan; Delphine Collomb; Céline Gallazzini-Crepin; Alex Calizzano; Marie-Dominique Desruet; Dominique Pasquier; Michel Bolla; Daniel Fagret; Jean-Philippe Vuillez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-14       Impact factor: 9.236

9.  Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles.

Authors:  Rong Liu; Denis M Gilmore; Kimberly Ann V Zubris; Xiaoyin Xu; Paul J Catalano; Robert F Padera; Mark W Grinstaff; Yolonda L Colson
Journal:  Biomaterials       Date:  2012-12-08       Impact factor: 12.479

10.  The role of occupational upper extremity use in breast cancer related upper extremity lymphedema.

Authors:  Gulgun Tahan; Ronald Johnson; Lisa Mager; Atilla Soran
Journal:  J Cancer Surviv       Date:  2009-12-06       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.